| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.11 | 0.09 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.08 | 0.09 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.09 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.055 | 0.09 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.1 |